← Back to products

Add to wishlist

Click to enlarge

Sermorelin 10mg

Name: Sermorelin 10mg
SKU: SERM10MG
Price: 80 USD
Availability: InStock

$80.00

≥99% purity · HPLC verified · MS confirmed How we test →

Products will arrive in a lyophilized (powder) form for maximum stability

Sermorelin is a synthetic 29-amino acid peptide corresponding to the active fragment of growth hormone-releasing hormone (GHRH 1-29) — the shortest sequence retaining full GH-releasing activity. It stimulates the pituitary to release growth hormone in a natural, pulsatile manner and was previously FDA-approved (as Geref) before commercial discontinuation. Supplied as a 10mg lyophilized vial at ≥99% HPLC purity, for research use only.

Add to compare

Add to wishlist

Add to compare

Add to wishlist

Free shipping on orders of $200+

COMPOUND NAME

Sermorelin

SYNONYMS

GHRH(1-29), Sermorelin acetate

CAS NUMBER

86168-78-7

MOLECULAR FORMULA

C₁₄₉H₂₄₆N₄₄O₄₂S

MOLECULAR WEIGHT

~3357.96 Da

STRUCTURE

Synthetic 29-amino acid peptide

PEPTIDE SEQUENCE

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH?

CHEMICAL STRUCTURE

Sermorelin growth hormone releasing peptide vial

Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

Source: PubChem

Sermorelin acts as a selective agonist of the growth hormone-releasing hormone receptor (GHRH-R), stimulating the pituitary to secrete endogenous growth hormone in a physiologic, pulsatile manner and activating the GH–IGF-1 axis.

GHRH Receptor (GHRH-R) Agonism

Stimulates pulsatile growth hormone (GH) secretion: Sermorelin binds to GHRH receptors on pituitary somatotrophs, enhancing cyclic AMP (cAMP) production and activating PKA and MAPK pathways, which trigger physiologic, feedback-sensitive GH release^1-3.

Elevates circulating IGF-1 levels: GH stimulates hepatic production of IGF-1, which exerts anabolic effects on muscle, bone, and metabolism^1,2,4,5.

Enhances pituitary responsiveness: Repeated sermorelin administration increases the amplitude and duration of GH pulses, improving long-term axis sensitivity^1,4.

Supports gonadotropic function: Preclinical and clinical data indicate modest increases in LH and testosterone following sermorelin treatment, possibly due to its upstream modulation of hypothalamic activity^2,3,4.

Receptor Binding Affinity: High-affinity GHRH receptor agonist; specific EC?

? values not widely reported in human systems^1,5.

Sermorelin’s agonism at the GHRH receptor effectively stimulates the release of endogenous GH in a pulsatile, physiologic pattern. This leads to increases in circulating IGF-1, with documented benefits in body composition, muscle mass, energy metabolism, and lipid balance. Sermorelin does not suppress natural GH axis regulation and may have better safety for long-term use than recombinant GH.

−20°C or below. Protect from light and moisture. Avoid repeated freeze-thaw cycles

Peptides; Growth Hormone Secretagogues; Endocrine Modulators

Typically administered via subcutaneous injection.
Well-tolerated; may cause transient injection site redness or tingling.
Does not cross-react with GH receptor or mimic insulin-like actions directly.
Maintains feedback-sensitive endocrine signaling (GH–IGF-1 axis)

Property

Description

CAS Number

2023788-19-2

Molecular Formula

C149H246N44O42S

Molecular Weight (MW)

~4813 Da

Mechanism of Action

Dual agonist at GIP and GLP-1 receptors; biased signaling, GIPR-dominant

Biological Activity

Improves glycemia, reduces weight, enhances insulin sensitivity

Supplied Form

Lyophilized powder

Purity

≥99% (HPLC)

Storage

−20°C, dry, light-protected

Drug Categories

Peptides; Incretin mimetic

Additional Notes

Long half-life, DPP-IV resistant, subcutaneous weekly dosing

For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.

Sermorelin is a synthetic peptide that mimics the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH), which are sufficient for full biological activity at the pituitary level. As a GHRH receptor agonist, Sermorelin stimulates the hypothalamic-pituitary-somatotropic axis, inducing pulsatile secretion of growth hormone (GH) from the anterior pituitary. This, in turn, activates hepatic production of insulin-like growth factor 1 (IGF-1), mediating anabolic and metabolic effects on muscle, bone, and fat metabolism. Unlike direct recombinant GH therapy, Sermorelin supports physiological feedback loops, maintains the natural rhythm of GH secretion, and reduces the risk of GH receptor downregulation. It is often explored as a more physiologic alternative for treating adult growth hormone insufficiency and age-related declines in GH and IGF-1 levels. Sermorelin has also been shown to increase lean body mass, enhance fat utilization, improve sleep quality, and potentially support gonadotropin release, with emerging use in functional hormone restoration protocols^1-5.

Increased Growth Hormone and IGF-1

: Studies in adults with age-related GH deficiency show significant increases in pulsatile GH secretion and IGF-1 levels, supporting anabolic and metabolic functions^2,3.

Improved Body Composition

: Sermorelin administration is associated with increases in lean body mass and reductions in body fat, particularly visceral adiposity, in GH-deficient individuals^2,4.

Preserved Feedback Control

: Unlike recombinant GH, sermorelin maintains normal hypothalamic-pituitary feedback, reducing the risk of overtreatment and supporting physiologic hormone rhythms^1,2,4.

Potential Reproductive Benefits

: Preliminary findings suggest sermorelin may modestly enhance LH and testosterone levels, indicating possible utility in male functional hypogonadism⁴.

Route of Administration

Subcutaneous

Dosing Frequency

Once daily

Reconstitute lyophilized powder in sterile bacteriostatic water for injection (0.9% benzyl alcohol)
Store reconstituted solution at 2–8°C and use within 14 days
Unreconstituted vials should be stored at −20°C in a dry, light-protected environment
Avoid repeated freeze-thaw cycles; aliquot as needed for stability
Stable for up to 12 months when stored properly in lyophilized form

Currently, no clinical trials are registered for Sermorelin. Earlier research primarily consisted of investigator-led studies and small-scale trials in adult and pediatric growth hormone insufficiency. While these studies demonstrated favorable outcomes in IGF-1 elevation, body composition, and GH pulsatility, most formal clinical development was discontinued in favor of newer secretagogues. Sermorelin is now predominantly used in off-label and research settings, supported by peer-reviewed literature but not under ongoing regulatory trial evaluation.

Walker, R.F. et al. Sermorelin: a review of its therapeutic potential in growth hormone insufficiency. Am. J. Ther. 3, 451–462 (1996). https://doi.org/10.2165/00063030-199912020-00007

Clark, R.V. et al. Effects of GH and GHRH analogs on body composition and hormonal profiles in aging. Aging Male 6, 159–171 (2003). https://doi.org/10.1080/13685530310001616308

Ishida, Y. & Yamada, S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Comm. 3, 206–222 (2020). https://doi.org/10.1002/rco2.31

Walker, R.F. et al. Sermorelin therapy: a physiological approach to adult-onset growth hormone insufficiency. Ther. Adv. Endocrinol. Metab. 9, 149–159 (2018). https://doi.org/10.21037/atm.2019.09.80

Yuen, K.C.J. et al. Pharmacokinetics of growth hormone-releasing hormone analogs in humans. Endocrine 14, 297–302 (2001). https://doi.org/10.1385/ENDO:14:3:297

This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →